Nicotian Haemodiagnosi Med E.E
Nicotian Haemodiagnosi Med E.E is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Nicotian Haemodiagnosi Med E.E?
The 2026-10-09 snapshot links Nicotian Haemodiagnosi Med E.E to 3 distinct CTIS trials. Recorded services include Laboratory services, Clinical haematology, High-sensitivity Troponin T, NT-proBNP, Serum Free Light Chain, Primary/ surrogate endpoint test, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nicotian Haemodiagnosi Med E.E?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nicotian Haemodiagnosi Med E.E conducted?
The linked trials record locations in 5 countries, including Greece, Germany, France, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Nicotian Haemodiagnosi Med E.E delivered services.
What can this page tell me about Nicotian Haemodiagnosi Med E.E's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nicotian Haemodiagnosi Med E.E. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nicotian Haemodiagnosi Med E.E.